Dana Haviland

Dana Haviland

Dana Haviland

 

Profile:

My rather unlikely background is in classical music performance, but have been at MSKCC since 1996, working through various departments and jobs. A family pet with lymphoma got me into research, and have been working in GI Oncology and HPB research since 2001. I am currently in charge of a database containing over 10,000 patients who have undergone resection for disease(s) of the pancreas. Working with attending staff and incoming Fellows, we are striving to create a comprehensive database of all patients diagnosed with diseases of the pancreas, inclusive of their treatment and outcomes.


Publications:

  1. Das, KK, Geng, X, Brown, JW, Morales-Oyarvide, V, Huynh, T, Pergolini, I et al.. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. Gastroenterology. 2019; :. doi: 10.1053/j.gastro.2019.05.014. PubMed PMID:31175863 .
  2. Lawrence, SA, Attiyeh, MA, Seier, K, Gönen, M, Schattner, M, Haviland, DL et al.. Should Patients With Cystic Lesions of the Pancreas Undergo Long-term Radiographic Surveillance?: Results of 3024 Patients Evaluated at a Single Institution. Ann. Surg. 2017;266 (3):536-544. doi: 10.1097/SLA.0000000000002371. PubMed PMID:28657939 .
  3. Winter, JM, Jiang, W, Basturk, O, Mino-Kenudson, M, Fong, ZV, Tan, WP et al.. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. Ann. Surg. 2016;263 (4):793-801. doi: 10.1097/SLA.0000000000001319. PubMed PMID:26135696 PubMed Central PMC4957241.
  4. Kemeny, NE, Schwartz, L, Gönen, M, Yopp, A, Gultekin, D, D'Angelica, MI et al.. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?. Oncology. 2011;80 (3-4):153-9. doi: 10.1159/000324704. PubMed PMID:21677464 PubMed Central PMC3123741.
  5. Yopp, AC, Schwartz, LH, Kemeny, N, Gultekin, DH, Gönen, M, Bamboat, Z et al.. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann. Surg. Oncol. 2011;18 (8):2192-9. doi: 10.1245/s10434-011-1570-1. PubMed PMID:21286939 PubMed Central PMC3137666.
  6. Jarnagin, WR, Schwartz, LH, Gultekin, DH, Gönen, M, Haviland, D, Shia, J et al.. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann. Oncol. 2009;20 (9):1589-95. doi: 10.1093/annonc/mdp029. PubMed PMID:19491285 PubMed Central PMC2731015.
  7. Kemeny, N, Capanu, M, D'Angelica, M, Jarnagin, W, Haviland, D, Dematteo, R et al.. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann. Oncol. 2009;20 (7):1236-41. doi: 10.1093/annonc/mdn769. PubMed PMID:19233901 .
  8. Gallagher, DJ, Zheng, J, Capanu, M, Haviland, D, Paty, P, Dematteo, RP et al.. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann. Surg. Oncol. 2009;16 (7):1844-51. doi: 10.1245/s10434-009-0348-1. PubMed PMID:19224284 .
  9. Tse, AN, Wu, N, Patel, D, Haviland, D, Kemeny, N. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother. Pharmacol. 2009;64 (5):935-44. doi: 10.1007/s00280-009-0945-5. PubMed PMID:19221752 .
Search PubMed